{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:53:39Z","timestamp":1791978819852,"version":"4.4.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Atopic dermatitis (AD) aetiology is not exactly identified, but it is characterized by pruritic skin reactions with elevation in the levels of inflammatory markers. Despite the fact that Corticosteroids are the mainstay therapy in the management of AD, they have many local and systemic adverse effects.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> The aim of this study is to evaluate the efficacy and safety of topical tacrolimus ointment in comparison to topical hydrocortisone cream in the management of the AD of children diagnosed with AD.<\/jats:p><jats:p><jats:bold>Patients and Methods:<\/jats:bold> This study was conducted on 200 children with AD. They were simply randomized into two groups, the tacrolimus group treated with 0.03% topical tacrolimus ointment and the hydrocortisone group treated with 1% hydrocortisone cream twice daily during the 3\u00a0weeks study period.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> At the end of the study, both the tacrolimus and hydrocortisone groups showed a significant decline in the mean serum level of IL-10, IL-17, and IL-23 (<jats:italic>p<\/jats:italic> &amp;lt; 0.05) when compared to their baseline levels. However, the tacrolimus group showed a more significant decrease (<jats:italic>p<\/jats:italic> &amp;lt; 0.05) in the mean serum level of IL-10, IL-17, and IL-23 as compared to the hydrocortisone group [Mean differences = 1.600, 95% CI: 0.9858\u20132.214; 1.300, 95% CI: 1.086\u20131.514 and 4.200, 95% CI: 3.321\u20135.079]. Moreover, the median mEASI decreased similarly from 32 to 21 in the tacrolimus group and from 30 to 22 in the hydrocortisone group (<jats:italic>p<\/jats:italic> &amp;gt; 0.05) [Median difference = \u22122.000, 95% CI: \u22122.651 to \u22121.349; Median difference = 1.000, 95% CI: 0.3489\u20131.651]. Mild to moderate transient stinging and erythema were the main adverse effects that showed higher incidence in the tacrolimus group than in the hydrocortisone group (<jats:italic>p<\/jats:italic> &amp;lt; 0.05). In most cases, they resolved within 3\u20134\u00a0days. Besides, tacrolimus ointment did not cause skin atrophy as compared to the hydrocortisone group (<jats:italic>p<\/jats:italic> &amp;lt; 0.05).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Tacrolimus ointment is more beneficial than hydrocortisone cream in managing AD in children in terms of lowering the inflammatory markers, however, there is no difference on the dermatitis severity scale. Moreover, tacrolimus is safer with a better side effect profile compared to hydrocortisone.<\/jats:p><jats:p><jats:bold>Trial Registration:<\/jats:bold> The trial is registered at <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> (<jats:ext-link>CT.gov<\/jats:ext-link> identifier: NCT05324618)<\/jats:p>","DOI":"10.3389\/fphar.2023.1202325","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T07:29:14Z","timestamp":1695281354000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["A comparative randomized clinical trial evaluating the efficacy and safety of tacrolimus versus hydrocortisone as a topical treatment of atopic dermatitis in children"],"prefix":"10.3389","volume":"14","author":[{"given":"Amal A.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radwa","family":"El Borolossy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman M.","family":"Salah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha S.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashwa M.","family":"Muharram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naglaa","family":"Elsalawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona G.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha O.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reham Y.","family":"El-Amir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba M. A.","family":"Elsanhory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourelhuda","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S.","family":"Adaroas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Montaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal A.","family":"El Kholy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/09546634.2019.1643447","article-title":"Dose-response association between vitamin D deficiency and atopic dermatitis in children, and effect modification by gender: A case-control study","volume":"32","author":"Ahmed","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"B2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1136\/bmj.38376.439653.D3","article-title":"Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials","volume":"5","author":"Ashcroft","year":"2005","journal-title":"BMJ"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005500.pub2","article-title":"Topical pimecrolimus for eczema","volume":"2","author":"AshcroP","year":"2007","journal-title":"Cochrane Database Sys Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"CD005203","DOI":"10.1002\/14651858.CD005203.pub2","article-title":"Dietary exclusions for established atopic eczema","volume":"2008","author":"Bath-Hextall","year":"2008","journal-title":"Cochrane Database Sys Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1398-9995.2006.01269.x","article-title":"Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis","volume":"62","author":"Bieber","year":"2007","journal-title":"Allergy"},{"key":"B6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1600-0625.2009.01024.x","article-title":"Atopic eczema or atopiform dermatitis","volume":"19","author":"Bos","year":"2010","journal-title":"Exp. Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4172\/2155-9899.1000110","article-title":"Th2 cytokines and atopic dermatitis","volume":"2","author":"Brandt","year":"2011","journal-title":"J. Clin. Cell. Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2165\/00128071-200506020-00001","article-title":"Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis","volume":"6","author":"Breuer","year":"2005","journal-title":"Am. J. Clin. Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1016\/j.jaci.2018.02.040","article-title":"Early-onset pediatric atopic dermatitis is characterized by TH2\/TH17\/TH22-centered inflammation and lipid alterations","volume":"141","author":"Brunner","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e2022155","DOI":"10.5826\/dpc.1201a155","article-title":"Topical and conventional systemic treatments in atopic dermatitis: Have they gone out of fashion?","volume":"12","author":"Calabrese","year":"2022","journal-title":"Dermatol Pract. Concept"},{"key":"B11","doi-asserted-by":"publisher","first-page":"104878","DOI":"10.1016\/j.phrs.2020.104878","article-title":"Topical corticosteroids for pediatric atopic dermatitis: Thoughtful tips for practice","volume":"158","author":"Chiricozzi","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.aller.2018.06.008","article-title":"Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel","volume":"47","author":"Chiricozzi","year":"2019","journal-title":"Allergologia Immunopathol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/bjd.15641","article-title":"Severity strata for eczema area and severity index (EASI), modified EASI, scoring atopic dermatitis (SCORAD), objective SCORAD, atopic dermatitis severity index and body surface area in adolescents and adults with atopic dermatitis","volume":"177","author":"Chopra","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.dsi.2015.06.004","article-title":"Taiwanese dermatological association consensus for the management of atopic dermatitis","volume":"33","author":"Chu","year":"2015","journal-title":"Dermatol Sin."},{"key":"B15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1610-0387.2011.07791.x","article-title":"Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues","volume":"10","author":"Czarnecka-Operacz","year":"2012","journal-title":"J. Dtsch. Dermatol Ges."},{"key":"B16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaci.2015.01.020","article-title":"Severe atopic dermatitis is characterized by selective expansion of circulating TH2\/TC2 and TH22\/TC22, but not TH17\/TC17, cells within the skin-homing T-cell population","volume":"136","author":"Czarnowicki","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaip.2014.03.006","article-title":"Skin barrier and immune dysregulation in atopic dermatitis: An evolving story with important clinical implications","volume":"2","author":"Czarnowicki","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/ddg.12074","article-title":"Comparison of effects of tacrolimus ointment and mometasone furoate cream on the epidermal barrier of patients with atopic dermatitis","volume":"11","author":"D\u00e4hnhardt-Pfeiffer","year":"2013","journal-title":"J Ger. Soc. Dermatology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1399-3038.2009.00895.x","article-title":"Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: Evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment","volume":"21","author":"Doss","year":"2010","journal-title":"Pediatr. Allergy Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/j.sder.2012.07.006","article-title":"Understanding and managing atopic dermatitis in adult patients","volume":"31","author":"Ellis","year":"2012","journal-title":"Semin. Cutan. Med. Surg."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jaci.2005.04.006","article-title":"Report of the topical calcineurin inhibitor task force of the American college of allergy, asthma and immunology and the American Academy of allergy, asthma and immunology","volume":"115","author":"Fonacier","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/all.13239","article-title":"Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis","volume":"73","author":"Furue","year":"2018","journal-title":"Allergy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of TH2\/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3906\/sag-1810-105","article-title":"Childhood atopic dermatitis: Current developments, treatment approaches, and future expectations","volume":"49","author":"G\u00fcr \u00c7etinkaya","year":"2019","journal-title":"Turk J. Med. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2340\/00015555924447","article-title":"Diagnostic features of atopic dermatitis","volume":"92","author":"Hanifin","year":"1980","journal-title":"Acta Derm. Venereol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jaci.2008.01.026","article-title":"The burden of disease associated with filaggrin mutations: A population-based, longitudinal birth cohort study","volume":"121","author":"Henderson","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","article-title":"Adverse effects of topical glucocorticosteroids","volume":"54","author":"Hengge","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1046\/j.1365-2133.2001.04344.x","article-title":"Ointment is evenly spread on the skin, in contrast to creams and solutions","volume":"145","author":"Ivens","year":"2001","journal-title":"Br. J. Dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.immuni.2013.08.007","article-title":"Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes","volume":"39","author":"Jakubzick","year":"2013","journal-title":"Immunity"},{"key":"B33","first-page":"57","article-title":"Comparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis","volume":"24","author":"Khan","year":"2016","journal-title":"J. Pak Assoc. Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5415\/apallergy.2011.1.2.53","article-title":"A proposal: Atopic Dermatitis Organizer (ADO) guideline for children","volume":"1","author":"Lee","year":"2011","journal-title":"Asia Pac Allergy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.jaad.2015.02.1116","article-title":"Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis","volume":"72","author":"Legendre","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1468-3083.2010.03789.x","article-title":"Balancing efficacy and safety in the management of atopic dermatitis: The role of methylprednisolone aceponate","volume":"25","author":"Luger","year":"2011","journal-title":"J. Eur. Acad. Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.iac.2014.09.008","article-title":"Atopic dermatitis in children: Clinical features, pathophysiology, and treatment","volume":"35","author":"Lyons","year":"2015","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"B38","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jaad.2010.03.044","article-title":"Superantigens in dermatology","volume":"64","author":"Macias","year":"2011","journal-title":"J. Am. Acad. Dermatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e00679","DOI":"10.1002\/prp2.679","article-title":"The impact of vitamin D supplementation as an adjuvant therapy on clinical outcomes in patients with severe atopic dermatitis: A randomized controlled trial","volume":"8","author":"Mansour","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"B40","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jaci.2014.11.015","article-title":"The translational revolution and use of biologics in patients with inflammatory skin diseases","volume":"135","author":"Noda","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2165\/00128071-200708040-00001","article-title":"Cancer concerns with topical immunomodulators in atopic dermatitis: Overview of data and recommendations to clinicians","volume":"8","author":"Patel","year":"2007","journal-title":"Am. J. Clin. Dermatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0140-6736(19):33174-5","article-title":"Emollients for prevention of atopic dermatitis in infancy","volume":"395","author":"Perrett","year":"2020","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1046\/j.1365-2133.2004.05782.x","article-title":"0.03% tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: Results of a randomized double-blind controlled trial","volume":"150","author":"Reitamo","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1067\/mai.2002.121832","article-title":"Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis","volume":"109","author":"Reitamo","year":"","journal-title":"J. Allergy Clin. Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1067\/mai.2002.121831","article-title":"Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis","volume":"109","author":"Reitamo","year":"","journal-title":"J. Allergy Clin. Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council","volume":"147","author":"Renert-Yuval","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1111\/all.12529","article-title":"Update on skin allergy","volume":"69","author":"Schlapbach","year":"2014","journal-title":"Allergy"},{"key":"B48","first-page":"304","article-title":"Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis - an open randomized comparative study","volume":"15","author":"Sikder","year":"2005","journal-title":"J. Pak Assoc. Dermatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/pai.12095","article-title":"Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization","volume":"24","author":"Silverberg","year":"2013","journal-title":"Pediatr. Allergy Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nri3831","article-title":"Type 2 cytokines: Mechanisms and therapeutic strategies","volume":"15","author":"Wynn","year":"2015","journal-title":"Nat. Rev. Immunol."}],"updated-by":[{"DOI":"10.3389\/fphar.2026.2021934","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1202325\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T07:29:19Z","timestamp":1695281359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1202325\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":50,"alternative-id":["10.3389\/fphar.2023.1202325"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1202325","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,20]]},"article-number":"1202325"}}